Fig. 1.

Post-ICT CTLA-4 Ig treatment increases antitumor efficacy. (A) Tumor growth curves of C57BL/6J mice harboring B16F10 tumors first treated with anti-CTLA-4 (clone 9H10) on days 7, 10, 13, and 16. Mice were then treated with CTLA-4 Ig which began on day 10, 13, or 16. Tumor growth curves of B16F10 tumors in C57BL/6J mice treated with (B) anti-CTLA-4 (clone 9H10), (C) anti-CTLA-4 (clone 9D9), (D) anti-PD-1, or (E) anti-CTLA-4 (clone 9H10) and anti-PD-1 in combination CTLA-4 Ig (concomitant). Mice were further treated with CTLA-4 Ig (post) on day 16. All experiments began with five mice per group. Representative experiment from duplicated experiments is shown.